Regeneron Pharmaceuticals, Inc.
REGN
$767.59
$0.930.12%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.50B | 4.58B | 4.46B | 4.50B | 4.41B |
| Total Depreciation and Amortization | 543.70M | 525.10M | 510.10M | 495.70M | 482.90M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -602.30M | -472.40M | 23.40M | -112.70M | 143.30M |
| Change in Net Operating Assets | 532.60M | 440.30M | -248.60M | -929.20M | -618.30M |
| Cash from Operations | 4.98B | 5.07B | 4.74B | 3.95B | 4.42B |
| Capital Expenditure | -898.40M | -849.30M | -889.80M | -851.30M | -755.90M |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 0.00 | 20.10M | 20.10M |
| Cash Acquisitions | -3.30M | -14.50M | -11.50M | -16.50M | -16.50M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 272.60M | 365.00M | 231.00M | 714.20M | -1.72B |
| Cash from Investing | -629.10M | -498.80M | -670.30M | -133.50M | -2.47B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 635.90M | 223.30M | 437.70M | 843.80M | 1.47B |
| Repurchase of Common Stock | -3.97B | -4.01B | -4.19B | -4.04B | -3.63B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -370.30M | -277.60M | -186.40M | -93.80M | -- |
| Other Financing Activities | -10.30M | -10.30M | -43.70M | -43.70M | -33.40M |
| Cash from Financing | -3.72B | -4.07B | -3.99B | -3.34B | -2.20B |
| Foreign Exchange rate Adjustments | 300.00K | -100.00K | 1.10M | 400.00K | -700.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 634.70M | 501.30M | 87.40M | 483.20M | -248.80M |